一分钟看懂
这是一项关于头颈部肿瘤的II 期研究，登记的药物或干预包括Becotatug Vedotin, Pucotenlimab, and Cisplatin，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Becotatug Vedotin, Pucotenlimab, and Cisplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- Histologically and/or cytologically confirmed, previously untreated (excluding diagnostic procedures) head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx, or larynx) with EGFR protein expression confirmed by immunohistochemistry (IHC),
- Clinical stage T2N2-3M0 or T3-4N0-3M0 (stage III-IV) per AJCC 8th edition.
- Age 18 to 70 years.
- ECOG performance status 0 or 1.
- Assessed by head and neck oncologist as locally advanced without distant metastasis.
- At least one measurable lesion per RECIST v1.1.
- Toxicity assessment per CTCAE v4.03 (for baseline evaluation).
- Adequate organ function to tolerate surgery:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07814287；登记信息更新于 2026-09-10。